Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Article

May 25, 2021

Additional Efforts Necessary to Implement New Recommended Age Range for Colorectal Cancer Screenings

Author(s):

Jamie Cesanek

In an accompanying editorial to the recently updated U.S. Preventive Services Task Force recommendation for colorectal cancer screenings, doctors suggested additional measures that would help increase the screening rate among eligible adults and potentially lower the mortality rate.

The U.S. Preventive Services Task Force (USPSTF) recently announced an updated recommendation for the screening of colorectal cancer, lowering the age to begin screenings from 50 to 45 and mandating insurance coverage.

But according to an accompanying editorial opinion piece published in JAMA Oncology, further research is still necessary to determine the causes of early-onset colorectal cancer in patients even younger than 45, and additional efforts to reach at-risk groups are necessary to implement these new guidelines.

Most early-onset colorectal cancer deaths occur between ages 45 to 49, said the authors, but data suggests the rate of increase in incidence is steepest in the youngest patients. Colorectal cancer incidence was found to be increasing by 2% per year among 20- to 29-year-olds versus 1.3% among 40- to 49-year-olds.

The authors also noted that implementation of the updated recommendation will be key to achieving prevention of the disease. Data shows that in 2018, the colorectal cancer screening rate in the United States was 68.8%. It was lower among the uninsured, low-income individuals and racial and ethnic minorities, proving that it’s crucial to reach nearly one third of the eligible-for-screening population.

In a change from the 2016 recommendations, the USPSTF conducted modeling studies in groups based on gender and race, finding that screening is equally effective in every population. However, disparities in colorectal cancer incidence and mortality persist and require further attention, according to Dr. Kimmie Ng, the editorial’s first author and director of the Young-Onset Colorectal Cancer Center at Dana-Farber Cancer Institute.

Black adults are 20% more likely to be diagnosed with colorectal cancer and 40% more likely to die than other groups, according to the American Cancer Society.

“So, we do hope that by lowering the screening recommendation to age 45 for everybody, that more Black Americans will also be getting screened,” said Ng, in an interview with CURE®.

“And hopefully, we're going to be making a dent in eliminating some of these disparities. We do think that the biggest reason for the disparities is unfortunately racial inequities in access to care and access to quality care. And so, we know that Black and Hispanic adults, for example, have a lower uptake of screening. So we really need to focus a lot of our public health efforts and public awareness campaigns in these communities where screening really will have a big impact.”

The editorial authors suggested several potential efforts beyond guidelines, quality metrics and public awareness campaigns that would encourage higher screening rates, such as an employer-provided “wellness day” for employees aged 45 to 75 to undergo screening or to be assisted with fecal immunochemical test (FIT) kits, appointment scheduling and daycare/transportation.

Other suggestions included occupational health services providing on-the-spot FIT screenings bundled with flu shots, health systems offering weekend or after-hours appointments for colonoscopies, safe ride services or the extension of post-procedure recovery periods for patients who lack social support, special efforts to reach vulnerable populations (underinsured, self-employed, mentally ill, disabled or incarcerated patients), physician accountability for prevention and outreach to patient families as well as improved communication from physicians who have diagnosed patients to their patients’ at-risk relatives.

As research continues to examine the causes of the recent rises in colorectal cancer incidence among younger age groups, scientists are considering environmental factors, the rise of obesity and sedentary behavior, according to Ng.

“We don't think that it's any change in the genetic makeup of human beings, because the change happened a little bit too abruptly and quickly, starting in the mid 1990s,” said Ng. “And most of the young people who are being diagnosed actually do not have a genetic syndrome or a family history of colon cancer.”

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Dr. Eng.
Image of man with black hair.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Image of woman with blonde hair.
Image of Dr. Fakih.
Image of Doctor with blonde hair.
Dr. Suneel Kamath is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, in Ohio.
Image of Dr. Scott Kopetz
Image of woman with black hair.
Related Content
Advertisement
Tecentriq/chemo combo reduces the risk of death vs chemo alone in dMMR, stage 3 CRC: © stock.adobe.com.
June 1st 2025

Tecentriq Plus Chemo Reduced Risk of Death vs Chemo Alone in dMMR Colon Cancer

Tony Berberabe
Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, stage 3 colorectal cancer.
Teri Greige with medals
February 16th 2023

The Sport of Cancer: How One Survivor Linked Ironman Training and Colorectal Cancer

Brielle Benyon
Teri Griege completed an Ironman triathlon in 2009, and less than a month later received a stage 4 colorectal cancer diagnosis. In this episode of Cancer Horizons, she shared her story.
Image of intestines.
May 20th 2025

Acoustic Cluster Therapy Shows Benefit in Colorectal Liver Metastases

Spencer Feldman
Tumors shrank more with the addition of acoustic cluster therapy to chemotherapy in colorectal liver metastases in the phase 1 ACTIVATE trial.
‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC
January 27th 2022

‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a woman living with colorectal cancer who was diagnosed 14 years ago at age 29 discusses what it was like to be the youngest person in the treatment room, and how she found another community of young survivors.
Image of intestines
May 6th 2025

Delving Into the Braftovi Plus Erbitux FDA Approval for BRAF+ mCRC

Ryan Scott
Dr. Cathy Eng discusses data that led to the FDA approval of Braftovi and Erbitux plus chemo for metastatic colorectal cancer with a BRAF V600E mutation.
FDA text.
May 1st 2025

Recapping Every FDA Approval Announced in April for Cancer Care

Ryan Scott
Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types.
Related Content
Advertisement
Tecentriq/chemo combo reduces the risk of death vs chemo alone in dMMR, stage 3 CRC: © stock.adobe.com.
June 1st 2025

Tecentriq Plus Chemo Reduced Risk of Death vs Chemo Alone in dMMR Colon Cancer

Tony Berberabe
Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, stage 3 colorectal cancer.
Teri Greige with medals
February 16th 2023

The Sport of Cancer: How One Survivor Linked Ironman Training and Colorectal Cancer

Brielle Benyon
Teri Griege completed an Ironman triathlon in 2009, and less than a month later received a stage 4 colorectal cancer diagnosis. In this episode of Cancer Horizons, she shared her story.
Image of intestines.
May 20th 2025

Acoustic Cluster Therapy Shows Benefit in Colorectal Liver Metastases

Spencer Feldman
Tumors shrank more with the addition of acoustic cluster therapy to chemotherapy in colorectal liver metastases in the phase 1 ACTIVATE trial.
‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC
January 27th 2022

‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a woman living with colorectal cancer who was diagnosed 14 years ago at age 29 discusses what it was like to be the youngest person in the treatment room, and how she found another community of young survivors.
Image of intestines
May 6th 2025

Delving Into the Braftovi Plus Erbitux FDA Approval for BRAF+ mCRC

Ryan Scott
Dr. Cathy Eng discusses data that led to the FDA approval of Braftovi and Erbitux plus chemo for metastatic colorectal cancer with a BRAF V600E mutation.
FDA text.
May 1st 2025

Recapping Every FDA Approval Announced in April for Cancer Care

Ryan Scott
Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.